Skip to main content

Table 2 Clinical and biological characteristics of human subjects investigated for detection of plasma BART miRNAs

From: Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells

  Patient code Age-sex- Country of origin Tumor histological type (1) Clinical Staging
(2)
EBV status Plasma viral DNA load (copies/ml)
(3)
Ebv-miR-BART 7-3p
2 -ΔCt X1000
      EBER detection on tumor sections (3) EBV serology Positive if > 0.2 Negative if < 0.1 (3)   
NPC
PATIENTS
EXO 14 52-M-Vietnam Non-keratinizing
Undifferentiated
T3N3M1 EBER+ Not tested 4202 250,5
  EXO 22 51-M-France Non-keratinizing
undifferentiated
T3N2M1 EBER + Not tested 1142 2360,3
  HEP 1 45-M-Cambodia Non-keratinizing
undifferentiated
T1N2M0 EBER + Not tested < 200 6
  EXO 32 40-F-Madagascar Non-keratinizing
undifferentiated
T3N2M0 EBER+ Not tested < 200 329,9
  HEP 2 58-M-France Non-keratinizing
undifferntiated
T3N1M0 EBER+ Not tested 1589 502,1
NON-NPC TUMOR CARRIERS HEP 5 69-M- France Adenocarcinoma
Multiple bone metastases of unknown primary
Not Applicable (NA) NA Anti-EBNA: 0,41
Anti-VCA: 4,08
< 200 3,47
  HEP 10 63-M-France Larynx squamous cell carcinoma T4N2M0 NA Anti-EBNA:7,13
Anti-VCA: 3,73
< 200 57,5
HEALTHY CONTROLS TBS 1 53-M-Algeria NA NA NA Anti-EBNA: 2,79
Anti-VCA: 2,46
< 200 37,7
  TBS 2 34-F-France NA NA NA Anti-EBNA: 0,07
Anti-VCA: 4,57
< 200 3,47
  TBS 3 29-F-France NA NA NA Anti-EBNA: 5,56
Anti-VCA: 1,65
< 200 79,8
  TBS 4 25-M-France NA NA NA Anti-EBNA: 0,05
Anti-VCA: 0
< 200 99
  1. (1) WHO histological classification (2) according to ESMO guidelines (reference 31) (3) See Materials and Methods